Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects-A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study

被引：0
|
作者：
Yuan, Jiandong
Huang, Yangqing
Ding, Haifeng
Jiang, Xiaohui
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-849-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
849-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study
    Fan, Yuxin
    Yuan, Jiandong
    Dong, Lichun
    Yu, Chongjing
    Ding, Haifeng
    Xie, Daosheng
    Guan, Runfang
    Li, Ruixia
    Zou, Wenhong
    Long, Shuxian
    Chen, Jion
    Huang, Yu
    Yang, Mei
    He, Jianchang
    Wen, Weibo
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2110 - 2119
  • [2] Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects-A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
    He, Kun
    Wei, Fang
    Chen, Hong
    Zhang, Yanyan
    Sheng, Zhen
    Wen, Qing
    DIABETES, 2023, 72
  • [3] Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HRS9531) in healthy subjects
    Wen, Q.
    He, K.
    Wei, F.
    Chen, H.
    Zhang, Y.
    Sheng, Z.
    Yin, L.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S326 - S327
  • [4] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Haiyan Li
    Yudong Wei
    Zhenhua Yang
    Shuang Zhang
    Xiuxiu Xu
    Mengmeng Shuai
    Olivier Vitse
    Yiwen Wu
    Marie T. Baccara-Dinet
    Yi Zhang
    Jianyong Li
    American Journal of Cardiovascular Drugs, 2020, 20 : 489 - 503
  • [5] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Li, Haiyan
    Wei, Yudong
    Yang, Zhenhua
    Zhang, Shuang
    Xu, Xiuxiu
    Shuai, Mengmeng
    Vitse, Olivier
    Wu, Yiwen
    Baccara-Dinet, Marie T.
    Zhang, Yi
    Li, Jianyong
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 489 - 503
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects -A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study
    Wu, Jingying
    Hu, Wei
    Du, Yijun
    Zhang, Qian
    Zhou, Renpeng
    Zhang, Qin
    Qin, Huiling
    Ye, Zi
    Xu, Yimei
    Feng, Sheng
    Shu, Chang
    Shen, Yu
    Fan, Yang
    DIABETES, 2023, 72
  • [7] A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-201 administered to healthy adult subjects
    Royal, Mike A.
    White, Jeffery
    Snyder, Ben
    Wei, Zheng
    Pan, Wubin
    Wang, Junying
    Sansone, Kenneth J.
    Yang, Xin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB159 - AB159
  • [8] Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study
    Irie, S.
    Matsumura, Y.
    Zdravkovic, M.
    Jacobsen, L. V.
    Kageyama, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (06) : 273 - 279
  • [9] A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
    Xie, Panpan
    Abildlund, Morten T.
    Baekdal, Tine A.
    He, Xuemei
    Lyauk, Yassine K.
    Patted, Usha Rani H.
    Ning, Zu
    Shi, Aixin
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3068 - 3077
  • [10] Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial
    Liu, Xiaoyan
    Zhang, Rui
    Li, Rong
    Wu, Qiong
    Pan, Chao
    Yu, Xiangqing
    Liu, Yuhui
    Wang, Benjie
    Yu, Shuwen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (12)
12345